Obinutuzumab with immunosuppressive therapies for treating lupus nephritis [ID6420]

Suggested remit: To appraise the clinical and cost effectiveness of obinutuzumab within its marketing authorisation for treating lupus nephritis.

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

6420

Provisional Schedule

Committee meeting: 1:

10 December 2025

Expected publication:

11 March 2026

Project Team

Project lead

Kate Moore

Email enquiries

If you have any queries please email [email protected]

External Assessment Group:

Newcastle NIHR TAR Team, Newcastle University

Stakeholders

Companies sponsors

Roche (obinutuzumab)

Others

Department of Health and Social Care

 

NHS England

Patient carer groups

Gene People

 

Kidney Care UK

 

Lupus UK

Professional groups

British Society for Rheumatology

 

Royal College of Physicians

 

UK Kidney Association

Associated public health groups

None

Comparator companies

GlaxoSmithKline (belimumab) (confidentiality agreement signed, participating)

 

Novartis (ciclosporin, mycophenolic acid) (confidentiality agreement signed, participating)

 

Otsuka Pharmaceuticals (voclosporin) (confidentiality agreement signed, participating)

 

Roche (rituximab, mycophenolate mofetil) (confidentiality agreement signed, participating)

 

Aspen (azathioprine) (confidentiality agreement not signed, not participating)

 

Astellas Pharma (tacrolimus) (confidentiality agreement not signed, not participating)

 

Baxter Healthcare (cyclophosphamide) (confidentiality agreement not signed, not participating)

 

Chiesi (tacrolimus) (confidentiality agreement not signed, not participating)

 

Celltrion Healthcare (rituximab) (confidentiality agreement not signed, not participating)

 

Dexcel Pharm (ciclosporin) (confidentiality agreement not signed, not participating)

 

Leo Laboratories (tacrolimus) (confidentiality agreement not signed, not participating)

 

Mylan (azathioprine, ciclosporin) (confidentiality agreement not signed, not participating)

 

Nova Laboratories (azathioprine) (confidentiality agreement not signed, not participating)

 

Pfizer (rituximab) (confidentiality agreement not signed, not participating)

 

Rosemont Pharmaceuticals (mycophenolate mofetil) (confidentiality agreement not signed, not participating)

 

Sandoz (cyclophosphamide, mycophenolic acid, rituximab, tacrolimus) (confidentiality agreement not signed, not participating)

 

Santen (ciclosporin) (confidentiality agreement not signed, not participating)

 

Strides Pharma (azathioprine) (confidentiality agreement not signed, not participating)

 

Teva Pharma (mycophenolate mofetil) (confidentiality agreement not signed, not participating)

 

Tillomed Laboratories (azathioprine, mycophenolate mofetil) (confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health - Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

NHS Wales Joint Commissioning Committee

 

Scottish Medicines Consortium

 

Welsh Government

Relevant research groups

Kidney Research UK

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual